Lumixyl Special Report – February 2011

Posted: February 14, 2011 at 1:57 pm

Lumixyl Cover

Aesthetic Trends & Technologies
Special Report - February 2011
Lumixyl Skin Brightening System

News for Dermatologists

HOW CAN LUMIXYL COMPLEMENT MY THRIVING HYDROQUINONE-DISPENSING PRACTICE?

By Felipe Jimenez, Ph.D., Envy Medical

Let’s face it. Hydroquinone has been the gold standard for treating hyperpigmentation for decades. In fact, hydroquinone continues to be the number one prescribed skin lightening agent globally. In years past, patients were given a prescription for hydroquinone (HQ) that they would fill at their neighborhood drugstore. Today, there is a growing number of dermatologists and other aesthetically oriented physicians who now dispense hydroquinone-based products directly to their patients. Once an afterthought, this practice model has become a core part of the patient offerings for physicians across the country. So why consider dispensing non-hydroquinone products to your patients?

SKIN BRIGHTENING PRODUCTS
There are several compelling instances where prescribing a non-hydroquinone skin brightener to your patients may be appropriate or even necessary. The Lumixyl Topical Brightening System incorporates new peptide technologies developed by Stanford University dermatology researchers for just such occasions. The following instances are just a few of the more common examples of when prescribing a non-hydroquinone regimen such as the Lumixyl Topical Brightening System is recommended:

Avoiding Chronic HQ Use
In most cases, it is recommended that patients stop using hydroquinone after using it continuously for 4 – 6 months. It simply is not meant to be an ongoing daily skin care agent. However, it is well known that discontinuing the use of a tyrosinase inhibitor, like hydroquinone, or other skinlightening agents may cause hyperpigmented spots to resurface. This is why it is recommended that patients begin using a non-hydroquinone maintenance regimen in order to preserve their even complexion. This is a perfect opportunity to…READ ON - Download Full Article NOW

For additional information on bringing the Lumixyl Topical Brightening System into your practice with a limited introductory offer, please visit http://www.envymedical.com or call 1-888-848-3633.

VISIT ENVY MEDICAL AT BOOTH #1365 DURING THE AMERICAN ACADEMY OF DERMATOLOGY MEETING IN NEW ORLEANS FEBRUARY 4-8, 2011.

ENVY Logo

About ENVY Medical
Envy Medical’s mission is to offer highly effective non-invasive skin rejuvenation therapies for patients suffering from either dermatologic or aesthetic conditions. The company’s lead products include SilkPeel®, a breakthrough system that combines precision non-invasive exfoliation with Dermalinfusion™, deep delivery of a diverse set of skin-specific solutions, all designed to improve and revitalize the skin. In fact Envy Medical (through it’s predecessor company, emed) is the inventor of Dermalinfusion, and holds a series of interlocking patents covering the technology.

The company also owns exclusive rights to a class of novel peptides that show clinical efficacy in the topical treatment of dermatologic indications. Developed by Dr. Basil Hantash’s team of dermatological researchers out of Stanford University, this ground-breaking technology encompasses the only peptide class clinically shown to significantly brighten skin and address hyperpigmentation. The company has introduced its first product line, under the brand name Lumixyl™. Recent studies show that Lumixyl™, incorporating a peptide chain of ten amino acids, treats hyperpigmentation more efficaciously than hydroquinone - the most commonly prescribed medication for the treatment of Hyperpigmentation.

Related Post

Comments are closed.

Archives